ras and p53 in the prediction of survival in Dukes’ stage B colorectal carcinoma

M A Bennett, E W Kay, H Mulcahy, L O’Flaherty, D P O’Donoghue, M Leader, D T Croke

Abstract

**Aims**—To determine possible associations between p53 allelic deletion, c-Ki-ras mutational activation, immunohistochemical detection of p53 and ras proteins, various clinicopathological variables, and patient outcome in 168 Dukes’ stage B colorectal carcinomas.

**Methods**—Allelic deletion at the p53 tumour suppressor gene locus was detected using polymerase chain reaction (PCR) based loss of heterozygosity (LOH) assays. Overexpressed proteins were detected using the CM1 polyclonal antibody. A PCR based assay was used to detect the presence of activating mutations at codon 12 of c-Ki-ras. Immunostaining was carried out using a monoclonal antibody to p21™.

**Results**—p53 LOH, CM1 immunostaining, c-Ki-ras mutational activation, and p21™ immunostaining were not predictive of survival by logrank analysis. Multivariate analysis using Cox regression did not predict survival in this group of tumours.

**Conclusions**—Aberrations in ras and p53 are unlikely to play an important role in the subdivision of patients with Dukes’ stage B colorectal carcinoma into more accurate prognostic strata. It is possible that later genetic events are more important in conferring a specific phenotype on the resultant Dukes’ stage B tumour. (J Clin Pathol: Mol Pathol 1995;48:M310-M315)

Keywords: p53, ras, Dukes’ stage B colorectal carcinoma, survival.

About one third of all colorectal tumours are designated Dukes’ stage B. Although this group of tumours is homogeneous from a pathological point of view, it exhibits significant clinical heterogeneity as exemplified by the variation in five year survival rates (50–78%) observed after surgery alone.'12 While Dukes’ staging is a proven prognostic indicator in colorectal carcinoma generally, there are no parameters available as yet which permit the subdivision of the patient cohort with Dukes’ stage B cancer into more accurate prognostic strata. Such parameters would assist in targeting patients for adjuvant therapy. This study seeks to address this issue by means of a retrospective study of the prognostic relevance of ras and p53 aberrations in Dukes’ stage B colorectal carcinoma.

Aberrations in many genes including the p53 tumour suppressor gene and c-Ki-ras oncogene occur frequently in the genesis of colorectal tumours. In vitro, certain combinations of oncogenes co-operate to transform primary cells. One such combination is ras and p53. Tumour cells harbouring activated ras and p53 have a growth advantage and may be selected for during tumorigenesis in vivo. Such genetic changes may correlate with tumour progression and may be markers of outcome which would be of particular importance in the treatment and management of patients.

Deletion of alleles in tumours from individuals heterozygous for polymorphisms can be assessed using loss of heterozygosity (LOH) assays. These assays depend on the presence of polymorphisms—for example, restriction fragment length polymorphisms (RFLPs), in the gene. Two such polymorphisms in the p53 gene at sites for the restriction endonucleases MspI, and AccII have been identified. p53 protein aberrations can be assessed using immunohistochemistry which detects overexpressed protein. Such assays have been used extensively in the assessment of p53 abnormalities in colorectal carcinoma. Activation of the c-Ki-ras oncogene can be detected by polymerase chain reaction (PCR) based techniques capable of detecting single point mutations in the gene and by immunohistochemical techniques which detect overexpressed protein.

While some studies have shown ras and/or p53 aberrations to be of importance in the prediction of survival in colorectal carcinoma, the relevance of these phenomena to survival prediction in Dukes’ stage B colorectal carcinoma is still unresolved.

**Methods**

In-series Dukes’ stage B colorectal carcinomas (n = 168) resected at a single institution (St Vincent’s Hospital, Dublin) between 1983 and 1989 were studied. Follow up to December 1994 was available for all 168 patients. Pathological variables (including Dukes’ staging, Jass staging and differentiation) were determined by a single histopathologist (EWK).

**Statistical Analyses**

Descriptive statistics and χ² analyses were carried out using Datadesk software (Data Description Inc., New York, USA). Kaplan–Meier survival curves were constructed and logrank and Cox regression analyses were carried out using Stata software (Stata Corp., Texas,
block were placed in a sterile 1-5 ml Eppendorf tube with 700 μl lysis buffer (50 mM Tris, pH 8.5, 1 mM EDTA, 0.5% Tween 20), boiled for 10 minutes, incubated for 48 hours at 37°C with protease K (0.4 mg/ml), and boiled to inactivate protease K. PCR products were generated on at least three separate occasions from all DNA templates to ensure that consistent results were obtained and to eliminate the possibility of inadvertent contamination from adjacent tumour/non-tumour material.

ALLELIC DELETION AT THE p53 TUMOUR SUPPRESSOR GENE LOCUS

TheMspI restriction endonuclease identifies a biallelic RFLP in intron 6 of the p53 gene and the AccII restriction endonuclease identifies a biallelic RFLP within exon 4 of the p53 gene. A novel 3' mismatch PCR primer was designed, exploiting the AccII site and the more cost-effective restriction endonuclease Smal (fig 1). The oligonucleotide primers used and reaction conditions for the PCR assay are outlined in table 1. Otherwise, assessment of allelic deletion was as described previously. DNA from 20 individuals was assayed to confirm that the Smal genotype reflects accurately the AccII genotype (data not shown). PCR dilution experiments were also carried out to verify that preferential allele amplification did not occur.

C-KI-ras MUTATIONAL ACTIVATION

The PCR assay used to detect the activating mutation at codon 12 of the C-KI-ras oncogene was that of Halassos et al. This technique is about 95% sensitive and can be expected to detect about 75% of all ras mutations in colorectal tumours. PCR products from non-

USA. Cancer related death was taken as the end point for all survival analyses.

EXTRACTION OF DNA FROM PARAFFIN WAX EMBEDDED MATERIAL

Haematoxylin and eosin stained slides of paraffin wax embedded tissue were used in the selection of tumour material and non-tumour mucosa adjacent to colorectal tumours. Tumour material with more than 70% neoplastic cells was considered suitable for PCR based analysis and serial sections from the same blocks were used for immunohistochemical analysis. DNA was extracted from paraffin wax embedded tumour and non-tumour material using a boiling/protease K method. Briefly, three 20 μm sections from a representative

---

**Table 1** Oligonucleotides and reaction conditions used for generating PCR products harbouring RFLPs within the p53 gene

<table>
<thead>
<tr>
<th>Reaction conditions</th>
<th>Oligonucleotide</th>
</tr>
</thead>
<tbody>
<tr>
<td>MspI</td>
<td>5'-AGTGTCTGGTTTGACAACTGGG-3'</td>
</tr>
<tr>
<td>20 pmol each</td>
<td>5'-GAGTCAAAATAGCAGCAGG-3'</td>
</tr>
<tr>
<td>35 cycles: 1-5 minutes 95°C, 1-5 minutes 61°C, 1-5 minutes 72°C</td>
<td></td>
</tr>
<tr>
<td>AccII (first)</td>
<td>5'-AGTGTCTGGTTTGACAACTGGG-3'</td>
</tr>
<tr>
<td>10 pmol each</td>
<td>5'-GAGTCAAAATAGCAGCAGG-3'</td>
</tr>
<tr>
<td>12 cycles: 2 minutes 95°C, 2 minutes 62°C, 2 minutes 72°C</td>
<td></td>
</tr>
<tr>
<td>AccII (second)</td>
<td>5'-AGTGTCTGGTTTGACAACTGGG-3'</td>
</tr>
<tr>
<td>20 pmol each</td>
<td>5'-GAGTCAAAATAGCAGCAGG-3'</td>
</tr>
<tr>
<td>35 cycles: 2 minutes 95°C, 2 minutes 64°C, 2 minutes 72°C</td>
<td></td>
</tr>
</tbody>
</table>

---

**Figure 2** Allelic deletion at the p53 tumour suppressor gene locus. Ethidium bromide stained polyacrylamide gel showing (M) molecular weight marker (HaeIII digested φX174 DNA); lane 1, undigested PCR product harbouring the exon 4 AccII RFLP in the p53 tumour suppressor gene; lane 2, AccII digested PCR product generated from normal peripheral leucocytes from a patient with colorectal carcinoma (the 259 bp fragment corresponds to one allele and the 160 and 99 bp fragments correspond to the other allele); lane 3, digested PCR product from the colorectal tumour. The disappearance of the 259 bp fragment is indicative of LOH or allelic deletion at the p53 tumour suppressor gene locus.
tumour material and from five tumours shown by the PCR based assay to harbour an activating mutation were sequenced using the fmol DNA Sequencing System (Promega Corp., Wisconsin, USA) to confirm the validity of the assay.

IMMUNOHISTOCHEMISTRY

Five micron sections from 168 colorectal tumour blocks were dewaxed and rehydrated through graded alcohols. Primary antibody NCL-p53-CM1 (Novocastra, Newcastle-upon-Tyne, UK.) or Dako-p21<sup>nat</sup> (Dako, Glostrup, Denmark) was applied and incubated overnight. Secondary antibody biotinylated swine anti-rabbit immunoglobulin was applied. Sections were then incubated with the avidin biotin peroxidase complex (Dako). Diaminobenzidine was used as chromogen and haematoxylin as nuclear counterstain. Positive and negative control sections were included with each batch of tumours. Staining was scored as either positive or negative and the presence of nuclear and cytoplasmic staining was recorded.

Results

Allelic deletion at the p53 tumour suppressor gene locus was observed in 34 (40%) of 85 informative cases. Preferential allele amplification was not observed (data not shown). No bias was observed in the frequencies of allelic deletion observed at the two polymorphic loci examined in the p53 gene. Six tumour samples previously shown to exhibit p53 allelic deletion by Southern blotting were assayed using the RFLP based PCR method described above which confirmed the presence of allele loss in these tumours (data not shown). Figure

**Figure 3** Colorectal tumours showing (A) nuclear and (B) cytoplasmic immunostaining detected with polyclonal antibody CM1.

**Figure 4** Ethidium bromide stained polyacrylamide gel showing (lanes 1 and 6) size marker (YaeHII digested 8X174 DNA); lane 2, MspI digested PCR product from non-tumour material (78 bp); lane 3, MspI digested PCR product from cell line SW 48 exhibiting the activating mutation at both alleles (99 bp); lane 4, MspI digested PCR product from tumour exhibiting the activating mutation at one allele (99 and 78 bp). Note: the 21 bp fragment is not shown.

**Figure 5** Nucleotide sequence of PCR products encompassing codon 12 of the c-Ki-ras oncogene from (A) tumour sample found, using the PCR based assay, to harbour the activating mutation at codon 12 of the c-Ki-ras oncogene; tumour is heterozygous for an activating mutation (G to T) in the coding sequence of the c-Ki-ras oncogene. (B) Tumour sample found, using the PCR based assay, to harbour the activating mutation at codon 12 of the c-Ki-ras oncogene; tumour is heterozygous for an activating mutation (G to A) in the coding sequence of the c-Ki-ras oncogene.
2 shows an example of LOH detected using the PCR based method.

Using the polyclonal antibody CM1, nuclear staining was assessed in 168 Dukes' stage B colorectal tumours. Nuclear staining was observed in 75 (46%) of 168 and cytoplasmic staining in 112 (67%) of 168 tumours. Interobserver variation in the determination of the presence, location and extent of p53 immunostaining using CM1 was very low. Forty colorectal tumours were selected randomly from this population and assessed independently by two pathologists; complete (100%) concordance was observed in their findings. This was part of a larger study of 121 tumours of varying origin in which disagreement between observers for the assessment of p53 immunostaining occurred in just eight of the 121 cases (EWK, manuscript in preparation). Figure 3 shows nuclear and cytoplasmic immunostaining detected with CM1.

Figure 4 shows wild-type and mutant c-Ki-ras alleles. Normal mucosa from 40 individuals examined was negative for the activating mutation. Wild-type c-Ki-ras was observed in mucosa 2 cm from the tumour margin (data not shown). Activating mutation at codon 12 was observed in 45 (40%) of 117 colorectal tumours. Figure 5 shows the sequence flanking codon 12 of the c-Ki-ras oncogene of two tumours, each exhibiting one wild-type allele and one mutant allele. p21supW immunostaining was detected in 78 (47%) of 167 colorectal carcinomas.

The data were tested for associations between ras and p53 abnormalities and a number of clinicopathological variables (table 2). Two significant associations were found; tumours which exhibited codon 12 c-Ki-ras mutation were smaller than those which did not (p = 0.049) and were more likely to be located in the rectum (p = 0.005). This latter finding was also observed for p21supW immunostaining (p = 0.024).

Survival analysis of the 168 patients with Dukes' stage B colorectal carcinoma revealed that none of the clinicopathological variables, either singly or in combination, was capable of predicting survival. Kaplan–Meier survival curves for p53 LOH, p53 immunostaining, c-Ki-ras mutational activation and p21supW immunostaining show that none of these parameters is predictive of survival (fig 6).

Discussion

One of the major difficulties complicating the management of Dukes’ stage B colorectal car-
Figure 6 Kaplan–Meier survival curves for (A) c-Ki-ras mutation (logrank p = 0.395), (B) p21 immunostaining (logrank p = 0.265), (C) p53 immunostaining (logrank p = 0.244), and (D) p53 LOH (logrank p = 0.687). In each graph Group 0 and Group 1 refer to patient groups negative and positive, respectively, for the parameter specified.

carcinoma is the clinical heterogeneity of this group of tumours. The elucidation of parameters capable of dividing the histologically homogeneous Dukes’ stage B cancers into more accurate prognostic strata would be of particular importance. This study, based upon a large in-series group of Dukes’ stage B colorectal tumours, addresses the specific question of whether ras and p53 aberrations have any value as prognostic parameters in this situation. In this regard, the study is distinct from a number of recent studies which have investigated these and other parameters in patients with colorectal carcinomas of mixed Dukes’ stage.14–17 20–21

LOH at the p53 tumour suppressor locus was observed in 40% of the Dukes’ stage B tumours studied. This value is lower than those reported in the literature—for example, frequencies of LOH of up to 83% have been observed in colorectal carcinoma.13 However, as most of the studies described to date do not distinguish between tumours on the basis of Dukes’ stage, comparisons may not be valid. Considerable care must be exercised in LOH assays to guard against bias in the assessment of allelic deletion. In this study specimens containing ≥70% neoplastic tissue were used, assays were performed in triplicate and preferential amplification of alleles was not observed. It is possible that the frequency of p53 allelic deletion increases with tumour progression. Indeed, distant metastases from colorectal tumours have been associated with 17p deletion.20–21 The frequency of p53 LOH observed here may reflect the relatively early position of the Dukes’ stage B stage in the progression of colon cancer.

The patterns of p53 immunohistochemical staining we have observed are similar to those reported by others.13–15 Detection of the protein by immunohistochemistry may be indicative of the presence of a mutation in the gene, due to binding with viral proteins or a result of DNA damage.22

In this study of Dukes’ stage B colorectal carcinomas 29% of the tumours exhibited an oncogenic mutation at codon 12 of the c-Ki-ras oncogene. This represents about 75% of all possible ras mutations in colorectal tumours and is not significantly different from that reported by other investigators for colon tumours, irrespective of stage.6,23–27 Mutational activation of the c-Ki-ras oncogene causes a conformational change and constitutive activation of the protein; its increased stability can then be detected immunohistochemically. It is also possible that the mutant protein is overexpressed as a result of amplification of the mutant allele. The monoclonal antibody used for immunohistochemical analysis detects all overexpressed forms of the protein (both mut-
ras and p53 in the prediction of survival in Dukes' stage B colorectal carcinoma

ant and wild-type), which may explain the higher incidence detected with immunohistochemistry compared with the PCR based assay. The observation of a higher frequency of c-Ki-ras mutation in rectal tumours may indicate site specificity of mutational activation of the oncogene.27

While other studies have indicated the importance of specific aberrations (including ras and/or p53) in predicting long term outcome following colorectal cancer resection, we found that these alterations were not closely related to survival in our group of patients with Dukes' stage B colorectal carcinoma. These tumours, which extend beyond the bowel wall without nodal metastases, are in a transition phase between locally invasive (Dukes' stage A) and metastatic (Dukes' stage C) disease and it may be that other features are more important in their progression than ras or p53 alterations. Indeed, we have found previously that protease production with subsequent destruction of local barriers to tumour spread is the most important prognostic indicator in this particular group of patients.28 Others have also found that features which indicate tumour migration through tissue planes, such as the presence of vascular invasion29 or the presence of immunohistochemically detected lymph node micrometastases,30 are important prognostic factors in those patients with Dukes' stage B cancer. Thus, while ras and p53 alterations seem to be potential prognostic indicators when all colorectal cancer stages are considered, it may be that a study of other genetic aberrations will provide more precise prognostic information.

This work was supported by grants from the Health Research Board of Ireland and the Royal College of Surgeons in Ireland.

References


ras and p53 in the prediction of survival in Dukes' stage B colorectal carcinoma

M A Bennett, E W Kay, H Mulcahy, L O'Flaherty, D P O'Donoghue, M Leader and D T Croke

Clin Mol Pathol 1995 48: M310-M315
doi: 10.1136/mp.48.6.M310

Updated information and services can be found at:
http://mp.bmj.com/content/48/6/M310

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/